KLOW Peptide vs GLOW: How the Two Peptide Blends Compare — Components and Evidence
The comparison in plain terms
KLOW vs GLOW — the two names for two closely related research peptide blends. GLOW is the three-peptide blend: GHK-Cu, BPC-157 and TB-500 (the G, L and W of the name). KLOW is the four-peptide blend: it adds KPV (the K) to the three peptides already in GLOW.
The single structural difference is KPV — the anti-inflammatory tripeptide Lys-Pro-Val. KPV is what KLOW has that GLOW does not. That is the only mechanistic distinction between the two blends. In the aurora: GLOW has three lights (aurora-green GHK-Cu / polar-cyan BPC-157 / aurora-violet TB-500); KLOW adds a fourth — aurora-teal KPV. Same sky, one more light.
Neither blend is FDA-approved. Neither has been tested as a blend in a controlled study. Both are research-only co-formulations whose component-level evidence comes from separate single-peptide research. The KLOW peptide research record is documented throughout this site.
KLOW vs GLOW: structural comparison
The composition of the two blends at the canonical research-vial level:
| Component | KLOW (80 mg total) | GLOW (70 mg total) | |---|---|---| | GHK-Cu | 50 mg (~62.5%) | 50 mg (~71.4%) | | BPC-157 | 10 mg (12.5%) | 10 mg (14.3%) | | TB-500 | 10 mg (12.5%) | 10 mg (14.3%) | | KPV | 10 mg (12.5%) | — |
KPV's addition changes the blend's anti-inflammatory profile, at least on mechanistic grounds. KPV suppresses NF-kappaB and MAPK inflammatory signaling via PepT1-mediated uptake into inflamed epithelial and immune cells at nanomolar concentrations [3]. GLOW lacks this direct NF-kappaB arm. The GHK-Cu and BPC-157 components have indirect anti-inflammatory properties (SIRT1/STAT3 pathway for GHK-Cu [5], NO modulation for BPC-157), but the direct cytokine-suppression mechanism of KPV is unique to KLOW in this comparison.
KLOW is also the distinct compound from WOLVERINE (a separate blend with different components and different compositional intent — not a variant of GLOW or KLOW).
The KPV light: what it adds mechanistically
KPV's mechanism is described in depth on the klow stack page. In brief: it is transported into inflamed intestinal epithelial cells and macrophages by PepT1 (Km ~160 microM), inhibits NF-kappaB p65 nuclear import, suppresses MAPK ERK/p38, and reduces TNF-alpha, IL-6, IL-1beta and IL-8 at nanomolar concentrations [3]. In mouse models, oral KPV reduced colitis severity [3]; in a colitis-associated cancer model, PepT1-mediated KPV delivery reduced inflammation-driven tumorigenesis [12].
The PepT1 uptake route means KPV has a degree of tissue-selectivity unusual for a tripeptide: inflamed gut tissue takes it up preferentially. This is why community reports about the KLOW blend frequently cite gut-comfort benefits they attribute to the KPV arm — and why they describe KLOW as feeling more anti-inflammatory than the KPV-free GLOW. Those reports are anecdotal, not clinical evidence; the head-to-head comparison does not exist. But the mechanistic rationale for a difference is real.
KPV also carries its own caution: for people with autoimmune disease or active infection, suppressing NF-kappaB-driven inflammatory signaling is a theoretical concern (KPV dampens part of the immune response that may be needed). No human study has tested this for KPV or for the blend [3].
What neither blend has: the honest comparison
Despite the mechanistic rationale for both KLOW and GLOW, neither blend has been tested in a controlled study. The evidence base for both blends is entirely component-level — individual peptide studies, mostly in cells and rodents, with limited human data for any component. The KLOW vs GLOW comparison is therefore a mechanistic comparison, not an evidence-based clinical comparison.
The pharmacokinetic mismatch that applies to KLOW applies to GLOW as well: GHK-Cu, BPC-157 and TB-500 also have different clearance rates, and the short BPC-157 half-life (under 30 minutes [11]) applies in both blends. KLOW's addition of KPV — another fast-clearing tripeptide — does not fix the PK mismatch; it adds a fourth light that also does not stay lit at the same time as the others.
The research record for KLOW research is a single-component record. So is GLOW's. Comparing them honestly means comparing one set of component-level extrapolations with another. That is what this page does.
See KLOW references for the full citation record.